Structure Therapeutics Announces Proposed $500 Million Public Offering of American Depositary Shares and Pre-Funded Warrants GlobeNewswire December 08, 2025 SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) — Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced the commencement […]

Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock GlobeNewswire December 08, 2025 BRISBANE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) — Vera Therapeutics, Inc. (“Vera Therapeutics”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced its plans to commence a public offering,

Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common Stock GlobeNewswire December 08, 2025 CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc.(R) (“Fulcrum”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that it has commenced

Arbe RoboticsLtd. (Nasdaq: ARBE) (TASE: ARBE) (“Arbe” or the “Company”), a global leader in perception radar solutions, today announced that, subject to approval of the bondholders,it proposes to extend to December 31, 2026 the deadline for meeting the conditions under its series A convertible bonds for the release of the proceeds raised from the issuance

Calumet, Inc. (NASDAQ: CLMT) (“Calumet”) announced today that it plans to attend the Wells Fargo 24th Annual Energy & Power Symposium on Wednesday, December 10th and will hold one-on-one investor meetings throughout the day. About Calumet Calumet, Inc. (NASDAQ: CLMT) manufactures, formulates, and markets a diversified slate of specialty branded products and renewable fuels to

HACKENSACK, NJ / ACCESS Newswire / December 8, 2025 / Champions Oncology, Inc. (CSBR), a leading translational oncology research organization, will report its financial and operational results for the second quarter ended October 31, 2025, on Monday, December 15, 2025, after market close. The company will host a conference call to discuss the results that

(NASDAQ:ASTI), THORNTON, Colo., Dec. 08, 2025 (GLOBE NEWSWIRE) — Ascent Solar Technologies, Inc. (NASDAQ: ASTI) (“Ascent” or the “Company”), today announced the closing of its previously announced private placement for the purchase and sale of an aggregate of 1,025,643 shares of common stock (or pre-funded warrants in lieu thereof), series A warrants to purchase up

(NASDAQ:ARQT), WESTLAKE VILLAGE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Amit Munshi has been appointed to the Arcutis Board of Directors effective December 4, 2025, and announced the retirement of founder and long-serving Board member Bhaskar

Ascent Solar Technologies Announces Closing of Up to $5.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules $2 million upfront with up to approximately $3.5 million of potential aggregate proceeds upon the exercise in full of warrants GlobeNewswire December 08, 2025 THORNTON, Colo., Dec. 08, 2025 (GLOBE NEWSWIRE) — Ascent Solar Technologies, Inc. (NASDAQ: ASTI)

Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar Chaudhuri GlobeNewswire December 08, 2025 WESTLAKE VILLAGE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Amit Munshi has been appointed to